Malignant fibrous histiocytoma of the temporal bone with endocranial extension.

Cranial malignant fibrous histiocytomas are rare tumors. Most are hypervascular, destructive masses that are similar to other malignant lesions and to malignant fibrous histiocytomas found elsewhere in the body. We describe a myxoid malignant fibrous histiocytoma of the temporal bone, possibly of dural origin, with features that more closely resembled a meningioma at CT, MR imaging, and angiography.     

Pharmacokinetics of orally administered norethisterone enanthate in rabbit, monkey, and women

Norethisterone enanthate (NET-En), an established intramuscular long-acting contraceptive agent, has previously been shown to be effective in inhibiting fertility in two rodent species even 4 days after oral ingestion. Pharmacokinetics of NET and NET-En were studied after oral and intramuscular doses in two animal species and a few women. The results suggest that the NET-En was absorbed within a day in all the species after oral dose. The estimates of relative bioavailability ranged from 13 to 51% in rabbits, monkeys, and women. The elimination half-life was 5–10 days. The presence of the active component, NET, in the circulation over the experimental period of 15 days suggests that NET-En could be useful as a long-acting oral pill. The suppression of progesterone levels during the luteal phase of menstrual cycle in women also supports this finding.     

香菇多糖注射液对慢性乙型肝炎外周血单个核细胞膜IL—2受体表达的影响

The effects of lentinan on peripheral blood mononuclear cell (PBMC) expression of IL-2 receptor in patients with chronic hepatitis B in vitro and in vivo were studied. The expression percentage of IL-2 receptor in 44 patients with chronic hepatitis before treatment was 36.74 +/- 7.74, which was lower than healthy subjects, and was 48.92 +/- 3.79 after 2 months treatment of lentinan, which was approximated the normal control. PBMC from 30 patients with chronic hepatitis B were cultured in vitro with or without lentinan. The percentage of expression IL-2 receptor was 12.81 +/- 2.62 without lentinan and was 35.70 +/- 4.87 in the presence of lentinan. The concentration of lentinan stimulating expression of IL-2 receptor was between 0.2 to 200 g.ml-1. The results suggest that lentinan stimulates expression of IL-2 receptor on PBMC, which is associated with the therapeutic effectiveness of lentinan treatment.